Core Viewpoint - The article highlights the successful closing of the KKR Innovation Fund III, which has reached a management scale of $1 billion, making it the largest AI-focused fund in EU history. The fund aims to drive deep applications of AI across key industries such as digital healthcare, fintech, consumer goods, and transportation and energy [1]. Investment Focus - KKR's investment strategy emphasizes the importance of AI serving specific scenarios and solving real problems, focusing on systematic solutions rather than just technological tools. The fund is particularly interested in early-stage to growth-stage projects, with individual investments ranging from $5 million to $80 million [2][5]. - The fund has not engaged in investments related to general large models or underlying infrastructure, adhering to a strategy that prioritizes practical applications and ecosystem development [5]. Globalization and Local Expertise - A significant feature of the fund is its global reach, with new limited partners (LPs) from South America, including Vale and COPEC, expanding its regional diversity while maintaining a strong industry focus. The fund has established local offices in key markets to better understand and navigate local ecosystems [1][6]. - KKR's advantages in the AI investment landscape include local offices in Asia, Europe, and the US, as well as a network of industry LPs that enhance its understanding of how AI products can be implemented in specific industry scenarios [6][7]. Long-term Vision - The fund views AI as a long-term proposition rather than a short-term profit opportunity, emphasizing the need for resilient entrepreneurs to build algorithmic capabilities, business models, and talent systems from an industry perspective [8]. - KKR aims to provide not only capital but also global vision, industry insights, and resource collaboration to help companies navigate early uncertainties and achieve scalable growth across markets [8].

Core Viewpoint - KKR Fund has successfully raised $1 billion, establishing the largest AI-focused fund in EU history and the largest venture capital fund in Europe [2][4]. Fund Overview - The KKR Innovation Fund III has a management scale of $1 billion and aims to drive deep applications of AI in key industries such as digital healthcare, fintech, consumer, and mobility & energy [2][4]. - The fund will invest in high-growth companies across major regions including China, Southeast Asia, Europe, and North America [2]. Investment Strategy - KKR Fund focuses on the deep application of AI in specific industries rather than just investing in AI infrastructure or models [5][6]. - The fund's investment size ranges from $5 million to $80 million, allowing for leading and co-leading investments as well as follow-on funding [6]. Portfolio and Partnerships - The fund has already invested in 15 high-growth companies, including notable names like "Xinghai Tu" and "Aochuang Guangnian" [7]. - KKR Fund has established a global ecosystem by collaborating with nearly 30 Fortune 500 companies, enhancing its ability to connect startups with industry resources [7][9]. Global Perspective - KKR Fund's founder, Cai Mingpo, emphasizes the importance of helping companies navigate cross-border and international cooperation [9]. - The fund has a unique global investment platform and industry ecosystem, managing over €7 billion [9]. Market Sentiment - There is a growing interest from global investors, particularly from Europe, in investing in Chinese technology companies, reflecting a shift in attitude towards Chinese assets [13][14]. - Major investment firms like Bridgewater and Goldman Sachs have recently expressed bullish sentiments towards Chinese assets, indicating a potential revaluation of these assets [14].

Core Viewpoint - Sanofi is showcasing its innovative products at the 2025 China Beijing International Science and Technology Industry Expo, emphasizing its commitment to advancing immunology and local healthcare integration in China [1][2] Group 1: Company Strategy - China is Sanofi's second-largest market, and the company is accelerating the introduction of over 60 innovative drugs and vaccines in the country [1][2] - Sanofi has established four local R&D centers in Beijing, Shanghai, Chengdu, and Suzhou, contributing to over 90% of its global R&D projects [2] Group 2: Collaboration and Partnerships - Sanofi collaborates with local biopharmaceutical companies like Jixing Pharmaceutical and Tianjing Biotech to advance research in oncology and immunology [2] - The company has formed a specialized pharmaceutical innovation fund with KKR to expedite the commercialization of local research outcomes [2] Group 3: Production and Supply Chain - Sanofi has developed a large-scale local production and supply network covering the Beijing-Tianjin-Hebei, Yangtze River Delta, and Greater Bay Area [2] - The Beijing production base in Yizhuang is the largest insulin injection production facility for Sanofi in the Asia-Pacific region [2]

Group 1 - The 2025 Beijing International Technology Industry Expo focuses on strategic emerging industries, particularly biomedicine, showcasing the achievements of Beijing's international technology innovation center [1] - Sanofi highlights its commitment to immunology innovation and local scientific ecosystem development, presenting nine breakthrough therapies across key disease areas [1] - Sanofi has introduced over 60 innovative drugs and vaccines to China, addressing seven of the top ten deadly diseases in the country [1] Group 2 - China is Sanofi's second-largest market, with over 90% of its global R&D projects involving Chinese participation, establishing China as a critical component of Sanofi's global R&D strategy [2] - Sanofi collaborates with leading local biopharmaceutical companies to accelerate the development of cutting-edge therapies in oncology and immunology [2] - The company has established a special pharmaceutical innovation fund in partnership with KKR to facilitate the commercialization of local research achievements [2] Group 3 - In December 2024, Sanofi announced a €1 billion investment to build an insulin production facility in Beijing, marking the largest single investment by the company in China [3] - Sanofi has developed a large-scale local production and supply network covering key regions in China, including Beijing-Tianjin-Hebei, the Yangtze River Delta, and the Greater Bay Area [3] - The company aims to strengthen its integrated industrial chain from R&D to production and operations in China, enhancing local healthcare development [3]

Core Viewpoint - Sanofi showcased its global innovative products at the 2025 Beijing International Technology Industry Expo, emphasizing its commitment to the Chinese market and its role in advancing the local biopharmaceutical ecosystem [1][3]. Group 1: Company Strategy and Market Position - Sanofi focuses on immunology innovation, presenting nine breakthrough therapies addressing key disease areas such as respiratory diseases, skin immunity, and metabolic diseases [3]. - The company has introduced over 60 innovative drugs and vaccines to China, covering seven of the top ten deadliest diseases in the country, thereby addressing unmet medical needs [3]. - China is Sanofi's second-largest market, and the company aims to leverage global resources to enhance local practices and accelerate the translation of pharmaceutical innovations [3]. Group 2: Research and Development - Sanofi has established four local R&D centers in Beijing, Shanghai, Chengdu, and Suzhou, creating a nationwide research network [3]. - Over 90% of Sanofi's global R&D projects involve China, highlighting the country's significant role in the company's innovation capabilities [3]. Group 3: Local Partnerships and Collaborations - Sanofi collaborates with leading local biopharmaceutical companies such as Jinxing Pharmaceutical and Tianjing Biotech to advance research in oncology and immunology [3]. - The company has formed a specialized pharmaceutical innovation fund with KKR to accelerate the commercialization of local research outcomes [3]. - Sanofi actively explores innovative business models with industry partners like Shanghai Pharmaceuticals to improve accessibility to primary healthcare services [3]. Group 4: Manufacturing and Investment - Sanofi has developed a large-scale local production and supply network covering the Beijing-Tianjin-Hebei, Yangtze River Delta, and Greater Bay Area [4]. - The Beijing production base, designed to international standards, is the largest insulin injection production facility in the Asia-Pacific region [4]. - In December 2024, Sanofi announced a €1 billion investment to establish a new insulin production base in Beijing, marking the company's largest single investment in China [4].

Fundraising Activities - In April 2023, a total of 28 fundraising activities were reported, indicating a vibrant investment environment [3] - The "Lilly Asia VI Fund" has been established, becoming the largest market-oriented fundraising biopharmaceutical VC fund in recent years, with a total commitment exceeding RMB 40 billion [5] - Prologis launched its first data center income fund, raising approximately RMB 2.6 billion, marking a significant entry into the data center investment space [7] - The "Kaihui Future Fund" was established in collaboration with L'Oréal and the Shanghai Jing'an District government, focusing on the evolving beauty market in China [8] - A fund initiated by Anhui entrepreneurs raised RMB 3 billion to invest in local science and technology enterprises [10] - Blackstone's latest European real estate fund raised €9.8 billion (approximately $10.6 billion), setting a record for third-party capital commitments in Europe [11] - The "Sanofi-Kaihui Pharmaceutical Innovation Fund" was established with a management scale of approximately RMB 2 billion, focusing on clinical-stage innovative drug pipelines [14] - The "Hubei Highway Development Fund" was launched with a total scale of RMB 30 billion, aimed at supporting modern transportation systems [16] - The Shanghai Biopharmaceutical M&A Fund completed its first closing with a scale of RMB 5 billion, supporting the high-quality development of the biopharmaceutical industry [18] - Eurazeo Capital V successfully raised approximately €3 billion, focusing on high-growth sectors such as technology-enabled business services and healthcare [20] New Fund Establishments - The "Zero One Venture" announced the completion of a new RMB 500 million fund, focusing on intelligent manufacturing and cross-border ventures [22] - The "Hongyi Investment" established a fund in Yixing with a first closing amount of RMB 606 million, targeting new energy and new materials [24] - The "Shaanxi Financial and High-tech Investment Fund" completed its second closing, focusing on semiconductor and AI sectors with a total scale of RMB 1.198 billion [26] - The "Pudong Venture Capital Fund" was launched with a target scale of RMB 1 billion, focusing on the biopharmaceutical industry [28] - Wuxi announced a market-oriented AI industry fund with a total scale of RMB 1 billion to support AI development [30] - The "Changfei Angel Fund" was launched with a total scale of RMB 600 million, focusing on optoelectronic information and AI sectors [32] - The "Low-altitude Economy Fund" in Sichuan was established to invest in eVTOL manufacturing, marking the province's first fund in this area [34] - The "Fangxi Purple Peak Venture Capital Fund" was registered, focusing on technology transfer and innovation in Hefei [36] - The "Yaan Chuan Business Emerging Industry Fund" was established with a registered scale of RMB 100 million, targeting seed and angel investments [39] - The "Wuhan University of Technology Innovation Fund" was launched with an initial fundraising scale of RMB 1 billion [41] Strategic Collaborations - The "AI Angel Fund" was launched by Shanghai Jiao Tong University, focusing on early-stage AI startups with a total scale of RMB 300 million [42] - The "Conch Private Equity Fund" was established, focusing on strategic emerging industries such as new materials and renewable energy [44] - The "Nongyin AIC Fund" was established in Tianjin, focusing on new generation information technology and intelligent manufacturing [56] - The "Hunan Gongrong Dici Venture Capital Fund" was registered, marking the first AIC venture capital fund in Hunan with a scale of RMB 1 billion [58] - The "Qingdao AIC Equity Investment Fund" was established, marking the first AIC fund in the city, with a focus on various strategic emerging industries [60]

以下文章来源于并购最前线 ，作者杨继云 并购最前线 . 投资界（PEdaily.cn）旗下，专注并购动态 欢迎加入投资界读者群 华人出手。 作者 I 杨继云 报道 I 投资界-并购最前线 投 资 界 - 并 购 最 前 线 获 悉 ， 已 有 近 百 年 历 史 的 摩 卡 壶 制 造 商 —— 比 乐 蒂 Bi a l e tti 将 被 收 购，买方是香港华人企业家St e phe n Che n g创办的投资机构Nu o Ca pit a l。 消息显示，双方已完成对收购协议的签署，Nu o Ca pit a l收购比乐蒂近79%的股份，收购 价格约为5300万欧元（约合4. 3亿人民币）。此次收购预计将于六月底完成，而作为交易 的一部分，比乐蒂将从米兰证券交易所退市。 至此，这个意大利咖啡壶品牌经过岁月洗礼，从国民家庭标配到经营困境丛生，最终将 正式完成卖身。 一个意大利国民老品牌 迎来华人新东家 19 93年，一个名为阿方索·比乐蒂的意大利商人提出了"Moka Ex pr e ss "的想法，推出世 界上第一个制作咖啡的摩卡壶，并由其创立的比乐蒂（Bi a l e tti）公司开始制造与销售。 从那 ...

Core Insights - Starry Sea has successfully completed A2 and A3 rounds of financing, raising over 300 million RMB, bringing total financing since 2025 to nearly 100 million USD [1][6] - The valuation of Starry Sea's A3 round has doubled compared to the A1 round earlier this year, with ongoing discussions for a new round at a valuation of 5 billion RMB [3][6] - The lead investor, KKR Fund, aims to leverage its global ecosystem resources to accelerate Starry Sea's development in the field of embodied intelligence [3][8] Financing Details - The A2 and A3 rounds were led by KKR Fund, with participation from Lenovo Capital, Haier Capital, and existing investors such as IDG Capital and Hillhouse Capital [5] - The A1 round, completed in February, raised nearly 300 million RMB, led exclusively by Ant Group, with additional investments from existing shareholders [5][6] - Cumulatively, the financing since the angel round in February 2024 has reached approximately 100 million USD [6] Valuation and Growth - Starry Sea's rapid valuation growth is attributed to its comprehensive business lines, including models, entities, and commercialization [6] - The company is recognized for its strong capabilities across the entire supply chain, making it one of the few companies in China with end-to-end AI algorithm capabilities and commercial validation [6] - If the valuation reaches 5 billion RMB, Starry Sea will position itself as a leader in the second tier of the industry, with top-tier companies valued over 10 billion RMB [6] Industry Outlook - KKR Fund expresses confidence in the potential of embodied intelligence in the global market, viewing it as a key pathway to achieving general artificial intelligence [8] - The sector is attracting significant investment, with multiple high-profile funding rounds announced recently, indicating a growing interest in embodied intelligence [8][9] - According to KPMG, the number of financing events in the humanoid robot sub-sector has increased significantly, with projections indicating a market size of 6 trillion RMB by 2050 in China [9]

「解码 LP 」系投资界旗下专注 LP 报道公众号，关注各地基金政策，捕捉 LP 最新动态，欢迎关注！ 根据公开信息统计：截至周四下午，本周（3月29日-4月3日）LP动态共26起。 LP 普洛斯募资，投向一个万亿赛道 投资界获悉，普洛斯最新推出的中国数据中心收益基金一期已完成募集，投资规模约2 6亿 人民币，投资人包括国内领先投资管理公司及知名国际机构投资人，普洛斯担任基金管理人 及资产管理人。 这是普洛斯推出的首个数据中心主题投资策略。普洛斯主要聚焦不动产和私募股权投资，目 前资产管理规模超8 0 0亿美元，已是全球基础设施江湖不可忽视的存在。此次推出的数据中 心基金，是其长期管理运营物流基础设施基金基础上，把私募基金拓展到数据中心这一新的 资产品类，可谓从零到一一个新的突破。 LP 安徽老乡，联手募集3 0亿 一群安徽老乡成立的基金来了。 近日举办的2 0 2 5徽商大会上，3 0亿元徽商产业基金正式启动，由联想、迈瑞、奇瑞、科大 讯飞、蔚来、阳光电源、国轩高科等知名徽商企业联合成立。接下来，该基金将重点投资徽 商科创企业和科创项目。 取自徽商，用之徽商。产业良性循环之风蔚然兴起。近年来，为进一步招商引 ...

Core Insights - L'Oréal is facing unprecedented challenges in the Chinese market, with a decline in sales for the first time in a decade, while global sales grew by 5.1% in 2024 [2][6] - The company is launching initiatives focused on beauty technology and AI innovation, including the first Beauty Tech Hackathon in China [1][5] - L'Oréal has established two new investment funds aimed at supporting emerging beauty brands and related industries in China [3][4] Investment Strategies - The "Kaihui Chuangmei Future Fund" will invest in growing beauty brands and related enterprises, while the "Meili Linghang Fund" will focus on early-stage beauty projects with technological innovation and sustainability [3] - L'Oréal's investment strategy has shifted towards growth-oriented beauty projects, with the establishment of "Meici Fang" to invest in beauty startups and breakthrough technologies [4][5] Market Dynamics - The Chinese beauty market is experiencing a slowdown, with a 1.1% decline in retail sales and a 9.4% drop in imported cosmetics in 2024 [2][6] - Domestic beauty brands have gained market share, reaching 50.4% in 2023, surpassing foreign brands [7] - L'Oréal is adapting to changing consumer preferences, focusing on the "Z generation," mature consumers, and male demographics as key growth segments [6][12] Consumer Engagement - The company emphasizes the importance of understanding consumer behavior, noting a shift towards value, quality, and cultural resonance in brand connections [6][7] - L'Oréal aims to expand its consumer base from 100 million to 150 million by 2030 [6] Retail Strategy - L'Oréal is transforming offline stores from sales points to experience centers, enhancing customer engagement through service and product experience [9][10] - The company plans to deepen its presence in lower-tier cities, with a focus on expanding its retail footprint in these markets [11][12]